Interferon-gamma releasing assay versus tuberculin skin testing for latent tuberculosis infection in targeted screening programs for high risk immigrants.
BACKGROUND
Recent immigrants from developing countries (<2 years since immigration) are at very high risk of active TB disease due to reactivation of latent infections acquired in the country of origin. In industrialized low-incidence TB countries targeted testing programs for high risk groups could allow the detection of latently infected persons who would likely benefit from a course of preventive treatment. In this study we evaluated the tuberculin skin test (TST) and interferon-gamma enzyme-linked immunosorbent assay (QuantiFERON TB-gold in tube, QFT-IT) strategies for TB infection screening programs in recent immigrants from highly endemic countries.


METHODS
This is a prospective cross-sectional study. Paired tests performed in 1,130 immigrants attending an outpatient ward, between 2005 and 2007 for any health problem were evaluated by intention-to-treat (ITT) and per-protocol (PP) analysis for efficiency and efficacy of screening program.


RESULTS
Positive TST and QFT-IT were observed in 36.04 versus 29.82% (ITT) and in 45.27 versus 30.22% (PP) respectively. A higher drop-out rate was observed for TST (20.35 vs. 1.33%) (p < 0.0001). Second level assessment was accepted by half of the TST positive patients. Overall agreement rate between 887 paired tests was fair (k = 0.38). Higher k values were observed for higher TB prevalence rate in the country of origin (k = 0.43), for TST induration diameters >20 mM (k = 0.47), in subjects aged 40-50 years (k = 0.41) and in unvaccinated persons (k = 0.40). In a multiple logistic regression model continent of origin, class of TB prevalence in the country of origin and contacts with TB patients were found to be significantly associated with the probability of TST and QFT-IT positive result. Low education levels were associated only to an increased risk of TST positive results.


CONCLUSIONS
The drawback of the TST screening strategy in recent immigrants from highly endemic countries is due to low sensitivity/specificity of the test and to high drop-out rate with an overall significant lowering in strategy efficacy/efficiency. The higher QFT-IT specificity prevents unnecessary overload of the health care system and, although more expensive, might represent a cost-effective alternative to TST in targeted screening programs directed to high risk populations.
Orlando
G
G
II Division Infectious Diseases, Infectious Diseases Department, L Sacco University Hospital, Via GB Grassi, 74, 20157, Milan, Italy. orlando.giovanna@hsacco.it
Merli
S
S
Cordier
L
L
Mazza
F
F
Casazza
G
G
Villa
A M
AM
Codecasa
L
L
Negri
E
E
Cargnel
A
A
Ferrarese
M
M
Rizzardini
G
G
D000328:Adult; D016009:Chi-Square Distribution; D003430:Cross-Sectional Studies; D054242:Emigrants and Immigrants / Q000706:statistics & numerical data*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism*; D055985:Latent Tuberculosis / Q000175:diagnosis* / Q000378:metabolism; D016015:Logistic Models; D008297:Male; D008403:Mass Screening / Q000379:methods; D011446:Prospective Studies; D012307:Risk Factors; D014374:Tuberculin Test / Q000379:methods*
D007371:Interferon-gamma
JAMA. 2005 Jun 8;293(22):2756-61
15941805
Thorax. 2002 Sep;57(9):804-9
12200526
Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):907-13
18470544
Am J Respir Crit Care Med. 2004 Jul 1;170(1):65-9
15087297
Rheumatol Int. 2007 Oct;27(12):1143-8
17503048
Eur Respir J. 2009 May;33(5):956-73
19407047
Am J Respir Crit Care Med. 2004 Jul 1;170(1):59-64
15059788
Clin Vaccine Immunol. 2007 Apr;14(4):477-80
17301213
Int J Tuberc Lung Dis. 2007 Nov;11(11):1183-9
17958979
Int J Tuberc Lung Dis. 2008 Jan;12(1):50-6
18173877
Clin Infect Dis. 2007 Oct 1;45(7):837-45
17806047
Clin Microbiol Infect. 2007 Aug;13(8):836-8
17501976
MMWR Recomm Rep. 2000 Jun 9;49(RR-6):1-51
10881762
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1376-95
10764337
Clin Diagn Lab Immunol. 2001 Nov;8(6):1089-96
11687445
Int J Tuberc Lung Dis. 2006 Nov;10(11):1192-204
17131776
Chest. 2007 Sep;132(3):959-65
17505029
J Rheumatol. 2008 May;35(5):776-81
18398944
AIDS. 2008 Nov 30;22(18):2471-9
19005270
Chest. 2007 May;131(5):1424-34
17494792
J Infect. 2007 Aug;55(2):164-8
17428542
Clin Infect Dis. 2007 Oct 1;45(7):826-36
17806046
Int J Tuberc Lung Dis. 2007 Nov;11(11):1190-5
17958980
MMWR Recomm Rep. 2005 Dec 16;54(RR-15):49-55
16357824
Clin Diagn Lab Immunol. 2005 Apr;12(4):491-6
15817755
Am J Respir Crit Care Med. 2007 Mar 1;175(5):514-20
17158278
Chest. 2007 Jun;131(6):1898-906
17565023
Ann Intern Med. 2007 Mar 6;146(5):340-54
17339619
Am J Respir Crit Care Med. 2005 Sep 1;172(5):631-5
15961696
PLoS One. 2008 Jan 16;3(1):e1441
18197251
J Infect Dis. 1999 Dec;180(6):2069-73
10558973
Am J Respir Crit Care Med. 2008 May 15;177(10):1164-70
18276940
Eur Respir J. 2002 Apr;19(4):765-75
11999007
Lancet. 2000 Sep 23;356(9235):1099-104
11009160
Clin Infect Dis. 2007 Aug 1;45(3):322-8
17599309
Intern Med. 2007;46(18):1543-9
17878640